Tirzepatide Weight Loss: The Trial Evidence

The short version

Tirzepatide weight loss in the large trials is among the largest body-weight reduction on record for any approved drug. In SURMOUNT-1, participants without diabetes who received the highest dose (15 mg once weekly) lost an average of 20.9% of their starting body weight over 72 weeks — compared to 3.1% with placebo. In a direct head-to-head comparison against the leading GLP-1-only drug, tirzepatide produced 20.2% weight loss versus 13.7%. These are group averages from controlled trials; results vary across individuals. This page covers the SURMOUNT trial data, the mechanism behind the weight effect, and what happens to weight after stopping.

Tirzepatide weight loss: SURMOUNT-1 primary results

SURMOUNT-1 enrolled 2,539 adults with a BMI of ≥30 kg/m², or ≥27 kg/m² with at least one weight-related complication, and without type 2 diabetes. Participants were randomised to once-weekly tirzepatide 5 mg, 10 mg, or 15 mg, or placebo, over 72 weeks with a 20-week dose-escalation period. The primary efficacy endpoint was mean percentage change in body weight at week 72 ^[6].

Results:

• 5 mg: -15.0% versus -3.1% placebo
• 10 mg: -19.5% versus -3.1% placebo
• 15 mg: -20.9% versus -3.1% placebo

All three doses were statistically superior to placebo. The most common adverse events were gastrointestinal and occurred predominantly during dose escalation, with most described as mild to moderate in severity. The 20-week titration schedule — starting at 2.5 mg and increasing every 4 weeks — was designed to minimise GI intolerance during escalation to the maintenance dose ^[6].

The weight-loss effect was not attributable to gastrointestinal adverse events. A post-hoc analysis confirmed that weight reduction occurred independently of whether participants experienced nausea, vomiting, or diarrhoea ^[13].

Body composition data from the SURMOUNT-1 DXA substudy found that approximately 25% of the weight lost was lean mass and approximately 75% was fat mass ^[2].

Head-to-head: SURMOUNT-5

SURMOUNT-5 is the first phase 3 open-label head-to-head trial comparing tirzepatide and a selective GLP-1 receptor agonist for weight management in adults with obesity without type 2 diabetes. The trial enrolled 751 adults and randomised them to the maximum tolerated dose of each agent once weekly for 72 weeks ^[8].

Primary result: least-squares mean body-weight change at week 72 was -20.2% with tirzepatide versus -13.7% with the comparator (p<0.001).

Secondary results: tirzepatide produced greater reductions in waist circumference and higher proportions of participants reaching each of the ≥10%, ≥15%, ≥20%, and ≥25% weight-loss thresholds at week 72 ^[8].

This is a direct, randomised, controlled comparison — not an indirect or modelled estimate.

Weight maintenance and weight regain after stopping

SURMOUNT-4 addressed what happens when tirzepatide is discontinued after initial weight loss. Participants who lost weight during an initial 36-week lead-in period were then randomised to continue tirzepatide or switch to placebo for a further 52 weeks. Those who continued tirzepatide continued to lose weight; those switched to placebo regained a substantial proportion of the weight lost ^[3].

Pooled withdrawal analyses across GLP-1-based agents document a mean weight regain of approximately 9.7 kg after stopping. This is consistent with the mechanistic rationale: the drug's appetite-suppressing and metabolic effects are active only during treatment. Regain has been documented alongside worsening cardiometabolic risk factors in withdrawal studies. This positions tirzepatide as a chronic therapy rather than a fixed-duration course for individuals seeking sustained weight management.

Clinical context: individual responses and the optimal treatment duration for a given person are questions for a prescribing clinician, not this research digest.

Cardiometabolic context: weight loss and the broader evidence base

The cardiometabolic significance of tirzepatide weight loss extends beyond the scale. Substantial weight reduction is associated with improvements in blood pressure, lipid profiles, insulin sensitivity, and cardiac structure and function. The dedicated evidence base includes:

• Lipid outcomes (13 RCTs): significant dose-responsive improvement in total cholesterol, LDL, HDL, and triglycerides ^[3]
• SUMMIT (HFpEF with obesity): reduced heart-failure events and improved functional status with tirzepatide-associated weight reduction ^[9]
• SURPASS meta-analysis (7 trials, type 2 diabetes): MACE-4 HR 0.80 (95% CI 0.57-1.11), point estimates favouring tirzepatide for cardiovascular death and all-cause mortality ^[2]

The weight-loss effect documented in SURMOUNT sits alongside — not in isolation from — this broader cardiometabolic evidence base. Details are on the Tirzepatide research page and in Tirzepatide references.